PM360

NOVEMBER 12, 2024

Before Sage, he served as president of Alnylam Pharmaceuticals, Inc. since 2007, and he previously held the position of chief operating officer when he first joined the company in 2003. Before his 17-year tenure at Alnylam, Mr. Greene was the general manager of Oncology at Millennium Pharmaceuticals, Inc.,

Food and Drug Administration 52

Food and Drug Administration Healthcare Provider Healthcare Healthcare 52

European Pharmaceutical Review

SEPTEMBER 22, 2023

Prior to joining Novimmune in 2002, she was Head of Immunology and Preclinical Pharmacology at the Serono Pharmaceutical Research Institute, a Senior Scientist and then Head of Immunology at the Glaxo Wellcome Research Institute in Geneva, and a Scientific Member of the Basel Institute for Immunology.

Food and Drug Administration 97

Food and Drug Administration Safety Patients Leads 97

Pharmaceutical Technology

JULY 23, 2008

” “Between 2003 and 2005 global sales for cancer-treating drugs grew by 40%.” . “And there’s a tremendous opportunity to meet their needs.”

Side effects 52

Side effects Marketing Pharmaceutical Sales 52

World of DTC Marketing

JANUARY 27, 2022

In 2003 President George W. March-in rights under Bayh-Dole have never been invoked, no doubt because the Pharmaceutical Research and Manufacturers of America, or PhRMA, has made clear that it would litigate. That made them liable to the Bayh-Dole march-in rights over high prices or inadequate supply.

Government 228

Government Pharmaceutical research Prescription Pharmaceutical 228